Reid M S, Herrera-Marschitz M, Terenius L, Ungerstedt U
Department of Pharmacology, Karolinska Institute, Stockholm, Sweden.
Brain Res. 1990 Sep 3;526(2):228-34. doi: 10.1016/0006-8993(90)91226-7.
The effects of unilateral injections of two substance P fragments, the N-terminal substance P (1-7) (SP1-7) and the C-terminal substance P (6-11) (SP6-11) into the substantia nigra, pars reticulata on dopamine (DA) release in the ipsilateral striatum of halothane-anaesthetized rats were studied using microdialysis. SP1-7 and SP6-11 were also tested for their ability to modify the DA stimulation produced by intranigral injections of SP or neurokinin A (NKA). In addition, the SP antagonist Spantide I was tested for its ability to modify the DA stimulation produced by an intranigral injection of SP1-7. Intranigral injections of SP1-7 (0.001-5.0 nmol) inhibited DA release after low doses (0.001-0.01 nmol), but stimulated DA release after high doses (0.1-5.0 nmol). Striatal dihydroxyphenylacetic acid (DOPAC) levels increased moderately after high doses of SP1-7 (1.0-5.0 nmol). Intranigral injections of SP6-11 (0.01-5.0 nmol) inhibited DA release, but enhanced striatal DOPAC levels, dose-dependently. SP1-7 (0.01-0.1 nmol), but not SP6-11 (0.1 nmol), blocked the stimulation of striatal DA release produced by intranigral SP (0.07 nmol). Neither SP1-7 (0.1 nmol) nor SP6-11 (0.1 nmol) could modify the stimulation of striatal DA release produced by intranigral NKA (0.09 nmol). The increase in DA release after a high dose of SP1-7 (1.0 nmol) was not modified by co-administration with Spantide I (0.07 nmol).(ABSTRACT TRUNCATED AT 250 WORDS)
利用微透析技术,研究了在氟烷麻醉的大鼠中,向黑质网状部单侧注射两种P物质片段,即N端P物质(1 - 7)(SP1 - 7)和C端P物质(6 - 11)(SP6 - 11)对同侧纹状体中多巴胺(DA)释放的影响。还测试了SP1 - 7和SP6 - 11改变由黑质内注射P物质或神经激肽A(NKA)所产生的DA刺激的能力。此外,测试了P物质拮抗剂Spantide I改变由黑质内注射SP1 - 7所产生的DA刺激的能力。黑质内注射SP1 - 7(0.001 - 5.0纳摩尔)在低剂量(0.001 - 0.01纳摩尔)时抑制DA释放,但在高剂量(0.1 - 5.0纳摩尔)时刺激DA释放。高剂量的SP1 - 7(1.0 - 5.0纳摩尔)后,纹状体二羟基苯乙酸(DOPAC)水平适度升高。黑质内注射SP6 - 11(0.01 - 5.0纳摩尔)抑制DA释放,但剂量依赖性地提高纹状体DOPAC水平。SP1 - 7(0.01 - 0.1纳摩尔)而非SP6 - 11(0.1纳摩尔)阻断了黑质内注射SP(0.07纳摩尔)所产生的纹状体DA释放刺激。SP1 - 7(0.1纳摩尔)和SP6 - 11(0.1纳摩尔)均不能改变黑质内注射NKA(0.09纳摩尔)所产生的纹状体DA释放刺激。高剂量SP1 - 7(1.0纳摩尔)后DA释放的增加不受与Spantide I(0.07纳摩尔)共同给药的影响。(摘要截断于250字)